John F. Ginascol - Feb 17, 2023 Form 4 Insider Report for ABBOTT LABORATORIES (ABT)

Role: EXECUTIVE VICE PRESIDENT
Signature: /s/ John F. Ginascol by Jessica H. Paik, Attorney-in-Fact
Stock symbol: ABT
Transactions as of: Feb 17, 2023
Transactions value $: $0
Form type: 4
Date filed: 2/22/2023, 05:56 PM
Previous filing: Dec 15, 2022
Next filing: Mar 2, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ABT	Common shares without par value	Award	$0	+14.3K	+12.75%	$0.00	126K	Feb 17, 2023	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ABT	Option (right to buy)	Award	$0	+56.3K		$0.00	56.3K	Feb 17, 2023	Common Shares	56.3K	$106.24	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes.
F2	Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 18,758 on February 17, 2024, 18,758 on February 17, 2025, and 18,759 on February 17, 2026.